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high levels of ROS. This could be further
potentiated by combination with drugs
that modulate specific signal transduction
pathways. Future work should concen-
trate on identifying appropriate oxidative
biomarkers as well as ROS-modulating
drugs to address this possibility clinically.
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Infantile hemangiomas represent the most common tumor of endothelial cell (EC) origin, yet the mechanisms
regulating hemangioma EC behavior are poorly understood. A new study by Jinnin et al. demonstrates that
enhanced VEGFR2 signaling in hemangioma ECs is caused by suppression of NFAT (nuclear factor of acti-
vated T cells)-dependent VEGFR1 expression.December 9, 2008 ª2008 Elsevier Inc. 429Infantile hemangiomas are benign local-
ized lesions, comprised primarily of aber-
rant endothelial cells (ECs), that appear
within the first weeks of life. These lesions
go throughaproliferation phaseduring the
first 6–10 months and slowly regress over
the following 5–10 years. During the invo-
lution phase, the vasculature undergoes
apoptosis and is replaced by fibrotic fatty
tissue. Depending on their location, hem-
angiomas can cause deformity or life-
threatening complications (Barnes et al.,
2007). Previously, Olsen and colleagues
isolated hemangioma ECs (hemECs)
from actively proliferating angiomas of
nine unrelated infants and showed that
these lines were clonal, arising from a
single progenitor cell (Boye et al., 2001).
These cells are thought to originate from
placental ECs or to be differentiated to-
ward the placental microvascular pheno-
type (Barnes et al., 2007). Although their
origin is uncertain, hemECshaveacharac-
teristic expression pattern that is stablymaintained in cultured cells and differs
from those of normal ECs. They have
increased rates of proliferation and en-
hanced VEGF-mediated migration (Boye
et al., 2001). However, until now, the mo-
lecular mechanisms driving the aberrant
behavior of hemECs remained unknown.
In a recent study, Jinnin et al. (2008)
showed that VEGFR2 signaling is constitu-
tively active in cultured hemECs due to de-
creased VEGFR1 expression. Since both
receptorsbindVEGF-A,VEGFR1 is thought
to negatively regulate VEGFR2 signaling by
acting as a decoy receptor for VEGF-A
(Olsson et al., 2006). Therefore, constitutive
VEGFR2 activity due to suppression of
VEGFR1 could explain the increased prolif-
eration and migration of hemECs.
With this in mind, the authors delved
further into how VEGFR1 is regulated in
hemECs as compared to normal ECs. Be-
cause both VEGFR1 (FLT1) transcript and
protein levels were minimal in hemECs,
Jinnin et al. sequenced part of the FLT1
Cancer Cell 14,promoter from all nine hemEC lines.
They demonstrated that a region of the
FLT1 promoter contains a binding site for
the transcription factor NFAT, providing
the first evidence that FLT1 represents
an NFAT target gene. Functionally, this
finding was critical to the characterization
of hemECsbecause theauthors alsodem-
onstrated that NFAT transcriptional activ-
ity is lower in hemECs than in normal
ECs.Hence, suppressionofNFAT-depen-
dent FLT1 transcription could help drive
the enhanced VEGF signaling of hemECs.
Looking upstream of NFAT to a cell-
surface receptor, Jinnin et al. also found
that reduced NFAT activation in hemECs
was associated with decreased b1 integ-
rin activity and decreased adhesion to
the b1 integrin substrates type I collagen
and fibronectin, despite equivalent sur-
face expression of b1 integrin between
both cell types.
Previous studies suggested a genetic
link between hemangioma growth and
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mutations. Examining the
coding sequences of 24 can-
didate genes (chosen for their
roles in controlling EC adhe-
sion, proliferation, etc.), Jinnin
et al. found heterozygosity for
nucleotide changes resulting
in amino acid substitutions
in three of the nine cultured
hemEC cell lines. One of
these mutations was in the
integrin-like protein tumor
endothelial marker 8 (TEM8).
While this mutation was not
found in DNA samples from
other individuals with a history
of hemangioma, its identifica-
tion suggested a role for
this protein in regulation of
NFAT activation and VEGFR1
expression. The authors
showed that wild-type TEM8
increased VEGFR1 expres-
sion and reduced VEGFR2
signaling in hemECs. In two
hemEC lines, they also found a germline
mutation of VEGFR2 (C482R) that had
a population frequency of 10%. This spe-
cific mutation was crucial for VEGFR2
regulation of VEGFR1 expression but
did not affect VEGFR2 expression or its
activity.
The authors also discovered a complex
between b1 integrin, TEM8, and VEGFR2
in both EC lines that was significantly
more abundant in hemECs. Identified
mutants of TEM8 and VEGFR2 also en-
hanced complex formation. These find-
ings suggested that TEM8 and VEGFR2
negatively regulate b1 integrin activation
and in turn suppress NFAT transcriptional
activity. Jinnin et al. then showed that de-
creased VEGFR1 expression, controlled
by NFAT, is linked to enhanced VEGFR2
signaling in hemECs and appears to be
negatively regulated by increased com-
plex formation between TEM8, VEGFR2,
and b1 integrin (Figure 1).
While the authors have made substan-
tial inroads into the mechanistic differ-
ences between normal ECs and hemECs
and put forth an interesting model
for hemEC dysfunction, some unan-
swered questions remain. For example,
integrin binding to the extracellular matrix
requires both alpha and beta integrin sub-
units. b1 integrin can interact with various
alpha subunits; therefore, it would be
interesting todeterminewhether aspecific
alpha subunit is also responsible for regu-
lation of NFAT. In normal ECs, VEGFR2
crosstalks with other integrins, such as
avb3 or avb5, to affect downstream
signaling (Hood et al., 2003; Mahabelesh-
war et al., 2007). Could the interaction
between VEGFR2 and avb3 or avb5 integ-
rin also be dysregulated in hemECs?
Although only one mutation each of
TEM8 and VEGFR2 was identified in this
study, could other mutations within the
same regions also be responsible for up-
regulated VEGFR2 signaling in hemECs?
An important caveat to this study is that
while these experiments were performed
with cultured cells derived from hemangi-
omas, it remains unclear whether this
same pathway is active in hemangiomas
in vivo. Unfortunately, there
are no physiologically rele-
vant in vivo models for infan-
tile hemangioma to date,
making it difficult to address
this issue (Ritter et al., 2007).
In conclusion, Jinnin et al.
have identified a molecular
pathway that may elucidate
the altered proliferation and
migratory behavior of hem-
ECs relative to normal ECs.
Currently, corticosteroids are
used to treat infantile heman-
giomas. However, their
mechanism of action is poorly
understood, and they can
have undesired side effects
such as growth retardation
and increased risk of infection
(Ritter et al., 2007). This
new model suggests that
treatment with anti-VEGF,
VEGFR2 kinase inhibitors, or
other agents affecting b1 in-
tegrin, TEM8, and NFAT
could be viable therapies to ameliorate
this condition.
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Figure 1. TEM8 and VEGFR2 Can Negatively Regulate b1 Integrin-
Mediated NFAT-Dependent VEGFR1 Expression through Complex
Formation
In normal endothelial cells (ECs), b1 integrin activation leads to NFAT-depen-
dent transcription of FLT1 (VEGFR1), the VEGF decoy receptor. However, this
pathway can be dampened by complex formation between b1 integrin,
VEGFR2, and TEM8. In hemangioma ECs (hemECs), constitutive VEGF signal-
ing may be due to enhanced complex formation in hemECs versus normal
ECs, which then leads to decreased FLT1 transcription.430 Cancer Cell 14, December 9, 2008 ª2008 Elsevier Inc.
